tradingkey.logo

Metavia Reports Positive Statistically Significant Results From Its Phase 1B Clinical Trial Of Da-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss And Favorable Safety Profile

ReutersJan 5, 2026 2:09 PM

MetaVia Inc MTVA.O:

  • METAVIA REPORTS POSITIVE STATISTICALLY SIGNIFICANT RESULTS FROM ITS PHASE 1B CLINICAL TRIAL OF DA-1726 IN METABOLIC DISEASE - DEMONSTRATING STRONG GLYCEMIC RESPONSE, SIGNIFICANT DIRECT HEPATIC EFFECTS, ROBUST WEIGHT LOSS AND FAVORABLE SAFETY PROFILE

  • METAVIA INC - 9.8 CM WAIST CIRCUMFERENCE REDUCTION AT DAY 54 IN STUDY

  • METAVIA INC - 23.7% REDUCTION IN LIVER STIFFNESS BY DAY 54 IN STUDY

  • METAVIA INC - 12.3 MG/DL FASTED GLUCOSE REDUCTION BY DAY 54 IN STUDY

  • METAVIA INC - 9.1% WEIGHT LOSS (21.2 LBS) BY DAY 54 IN STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI